versican Inhibitors
The diverse class of versican inhibitors represents a strategic array of chemical compounds designed to exert their effects on versican activity, a pivotal player in extracellular matrix remodeling. These inhibitors, acting either directly or indirectly, contribute to the intricate regulatory mechanisms governing tissue development and homeostasis. Fluorouracil and Gefitinib, indirect inhibitors, target the EGFR pathway, thereby modulating versican expression and influencing extracellular matrix dynamics. These compounds offer a nuanced approach to understanding the role of versican in cellular processes associated with tissue development. Doxycycline, another indirect inhibitor, impacts versican by modulating the TGF-β pathway. This intervention contributes to the maintenance of tissue homeostasis, emphasizing the interconnected nature of cellular signaling pathways involved in versican-mediated extracellular matrix remodeling. Gleevec, an indirect versican inhibitor, influences cellular processes related to tissue development through its targeting of the PDGF pathway. This demonstrates the versatility of inhibitors in unraveling the complex interplay between signaling cascades and versican-mediated effects.
Curcumin, modulating versican indirectly through the Wnt/β-catenin pathway, provides insights into the contribution of versican to tissue development and homeostasis. This inhibitor sheds light on the regulatory networks involved in extracellular matrix dynamics. Cisplatin induces DNA damage, activating p53, and indirectly modulates versican expression, revealing a link between genotoxic stress and versican-mediated effects. AG1478, targeting the EGFR pathway, offers a focused intervention to influence versican-mediated extracellular matrix remodeling. TGF-β Receptor Inhibitor II, by specifically interfering with TGF-β receptors, indirectly modulates versican, contributing to the maintenance of tissue homeostasis. Simvastatin, through modulation of the Rho GTPase pathway, indirectly influences versican expression, providing insights into the regulation of extracellular matrix dynamics. Dasatinib, targeting the Src pathway, and Stat3 Inhibitor, interfering with Stat3, both indirectly modulate versican expression, contributing to tissue homeostasis and shedding light on the intricate regulatory mechanisms associated with versican-mediated effects.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil is an indirect inhibitor of versican by targeting the EGFR pathway. As an antimetabolite, Fluorouracil inhibits thymidylate synthase, influencing DNA synthesis. Altered EGFR signaling, resulting from reduced thymidine levels, modulates versican expression. This indirect inhibition impacts cellular processes governed by versican-mediated extracellular matrix remodeling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an indirect inhibitor of versican by targeting the EGFR pathway. As a tyrosine kinase inhibitor, Gefitinib disrupts EGFR signaling, modulating versican expression. This indirect inhibition influences cellular processes governed by versican-mediated extracellular matrix remodeling, impacting cancer progression and invasion. | ||||||
Doxycycline-d6 | 564-25-0 unlabeled | sc-218274 | 1 mg | $16500.00 | ||
Doxycycline is an indirect inhibitor of versican by modulating the TGF-β pathway. As a tetracycline antibiotic, Doxycycline inhibits matrix metalloproteinases (MMPs), influencing TGF-β activation. Altered TGF-β signaling, resulting from MMP inhibition, modulates versican expression. This indirect inhibition impacts cellular processes governed by versican-mediated extracellular matrix remodeling, contributing to tissue homeostasis. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Gleevec is an indirect inhibitor of versican by targeting the PDGF pathway. As a tyrosine kinase inhibitor, Gleevec disrupts PDGF signaling, modulating versican expression. This indirect inhibition influences cellular processes governed by versican-mediated extracellular matrix remodeling, playing a role in tissue development and homeostasis. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin is an indirect inhibitor of versican by modulating the Wnt/β-catenin pathway. As a polyphenol, Curcumin inhibits Wnt signaling, influencing versican expression. This indirect inhibition impacts cellular processes governed by versican-mediated extracellular matrix remodeling, contributing to tissue development and homeostasis. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin is an indirect inhibitor of versican by modulating the p53 pathway. As a platinum-based chemotherapy agent, Cisplatin induces DNA damage, activating p53. Altered p53 signaling modulates versican expression, impacting cellular processes governed by versican-mediated extracellular matrix remodeling. | ||||||
Tyrphostin AG 1478 | 175178-82-2 | sc-200613 sc-200613A | 5 mg 25 mg | $96.00 $421.00 | 16 | |
AG1478 is an indirect inhibitor of versican by targeting the EGFR pathway. As a tyrosine kinase inhibitor, AG1478 disrupts EGFR signaling, modulating versican expression. This indirect inhibition influences cellular processes governed by versican-mediated extracellular matrix remodeling, playing a role in tissue development and homeostasis. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Simvastatin is an indirect inhibitor of versican by modulating the Rho GTPase pathway. As a statin, Simvastatin inhibits HMG-CoA reductase, influencing Rho GTPase activity. Altered Rho GTPase signaling modulates versican expression, impacting cellular processes governed by versican-mediated extracellular matrix remodeling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is an indirect inhibitor of versican by targeting the Src pathway. As a tyrosine kinase inhibitor, Dasatinib disrupts Src signaling, modulating versican expression. This indirect inhibition influences cellular processes governed by versican-mediated extracellular matrix remodeling, playing a role in tissue development and homeostasis. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stat3 Inhibitor is an indirect inhibitor of versican by specifically targeting Stat3. This small molecule interferes with Stat3 signaling, modulating versican expression. This indirect inhibition impacts cellular processes governed by versican-mediated extracellular matrix remodeling, contributing to tissue development and homeostasis. | ||||||